YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango
dc.contributor.author | Matthaios, D. | |
dc.contributor.author | Tolia, M. | |
dc.contributor.author | Mauri, D. | |
dc.contributor.author | Kamposioras, K. | |
dc.contributor.author | Karamouzis, M. | |
dc.date.accessioned | 2022-01-31T15:49:09Z | |
dc.date.available | 2022-01-31T15:49:09Z | |
dc.date.issued | 2021 | en |
dc.identifier.citation | Matthaios D, Tolia M, Mauri D, Kamposioras K, Karamouzis M. YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines. 2021;9(12):13. | en |
dc.identifier.pmid | 34944765 | en |
dc.identifier.doi | 10.3390/biomedicines9121949 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625031 | |
dc.description.abstract | Hippo pathway with its main molecule YAP is a crucial pathway for development, tissue homeostasis, wound healing, tissue regeneration, and cancer. In this review, we discuss the multiple effects of the YAP/Hippo pathway in the immune system and cancer. We analyzed a series of effects: extracellular vesicles enhanced immunity through inhibition of LATS1/2, ways of modulation of the tumor microenvironment, YAP- and TAZ-mediated upregulation of PDL1, high expression of YAP and PDL1 in EGFR-TKI-resistant cells, enhanced YAP activity in inflammation, and the effect of the Hippo pathway on T cells, B cells, Tregs, macrophages, and myeloid-derived suppressor cells (MDSCs). These pleiotropic effects render the YAP and Hippo pathway a key pathway for exploitation in the future, in order to enhance our immunotherapy treatment strategies in oncology. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.3390/biomedicines9121949 | en |
dc.title | YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango | en |
dc.type | Article | en |
dc.contributor.department | Department of Medical Oncology, Rhodes General Hospital, 85100 Rhodes, Greece | en |
dc.identifier.journal | Biomedicines | en |
dc.description.note | en] | |
refterms.dateFOA | 2022-04-19T12:34:41Z |